We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adverum Biotechnologies Inc | NASDAQ:ADVM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.43 | 4.30% | 10.43 | 9.75 | 44.43 | 10.69 | 10.00 | 10.10 | 900,531 | 05:00:01 |
The call is scheduled for Monday, May 4, 2020 beginning at 2:15 pm PDT (5:15 pm EDT). Individuals can participate in the conference call by dialing 1-866-420-8347 (domestic) or 1-409-217-8241 (international) and refer to “Adverum Biotechnologies’ Presentation and KOL Discussion of New Clinical Data from OPTIC Conference Call.” It is recommended call participants dial in 15 minutes in advance. The webcast will be accessible under Events and Presentations in the Investors section of the company's website. The archived audio webcast will be available on the Adverum website following the call and will be available for 30 days.
About Adverum BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. For more information, please visit www.adverum.com
Investor and Media Inquiries:
Investors:Myesha LacyAdverum Biotechnologies, Inc.mlacy@adverum.com1-650-649-1257
Media:Cherilyn Cecchini, M.D.LifeSci Communicationsccecchini@lifescicomms.com1-646-876-5196
1 Year Adverum Biotechnologies Chart |
1 Month Adverum Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions